KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Retained Earnings (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Retained Earnings for 17 consecutive years, with -$13.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 93.08% year-over-year to -$13.5 million, compared with a TTM value of -$13.5 million through Dec 2025, up 93.08%, and an annual FY2025 reading of -$13.5 million, up 93.08% over the prior year.
  • Retained Earnings was -$13.5 million for Q4 2025 at Biomarin Pharmaceutical, down from $200.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $231.5 million in Q2 2025 and bottomed at -$930.8 million in Q4 2021.
  • Average Retained Earnings over 5 years is -$215.6 million, with a median of -$12.1 million recorded in 2023.
  • The sharpest move saw Retained Earnings plummeted 18150.2% in 2021, then surged 200.31% in 2022.
  • Year by year, Retained Earnings stood at -$930.8 million in 2021, then grew by 15.21% to -$789.2 million in 2022, then increased by 21.24% to -$621.6 million in 2023, then soared by 68.68% to -$194.7 million in 2024, then soared by 93.08% to -$13.5 million in 2025.
  • Business Quant data shows Retained Earnings for BMRN at -$13.5 million in Q4 2025, $200.8 million in Q3 2025, and $231.5 million in Q2 2025.